As of 2024-12-14, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -1.03. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 181.33 mil USD. FATE's TTM EBITDA according to its financial statements is -176.53 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.2x - 17.3x | 16.0x |
| Forward P/E multiples | 15.9x - 23.3x | 16.9x |
| Fair Price | (24.37) - (26.45) | (25.17) |
| Upside | -1366.2% - -1474.1% | -1407.3% |
| Date | EV/EBITDA |
| 2024-11-27 | -1.83 |
| 2024-11-26 | -1.51 |
| 2024-11-25 | -1.35 |
| 2024-11-22 | -1.26 |
| 2024-11-21 | -1.12 |
| 2024-11-20 | -1.22 |
| 2024-11-19 | -1.19 |
| 2024-11-18 | -1.25 |
| 2024-11-15 | -1.09 |
| 2024-11-14 | -1.13 |
| 2024-11-13 | -1.19 |
| 2024-11-12 | -1.32 |
| 2024-11-11 | -1.44 |
| 2024-11-08 | -1.35 |
| 2024-11-07 | -1.43 |
| 2024-11-06 | -1.59 |
| 2024-11-05 | -1.51 |
| 2024-11-04 | -1.57 |
| 2024-11-01 | -1.35 |
| 2024-10-31 | -1.31 |
| 2024-10-30 | -1.39 |
| 2024-10-29 | -1.54 |
| 2024-10-28 | -1.64 |
| 2024-10-25 | -1.49 |
| 2024-10-24 | -1.60 |
| 2024-10-23 | -1.74 |
| 2024-10-22 | -1.84 |
| 2024-10-21 | -1.82 |
| 2024-10-18 | -1.87 |
| 2024-10-17 | -1.86 |
| 2024-10-16 | -1.86 |
| 2024-10-15 | -1.75 |
| 2024-10-14 | -1.75 |
| 2024-10-11 | -1.78 |
| 2024-10-10 | -1.68 |
| 2024-10-09 | -1.73 |
| 2024-10-08 | -1.77 |
| 2024-10-07 | -1.75 |
| 2024-10-04 | -1.86 |
| 2024-10-03 | -1.80 |
| 2024-10-02 | -1.86 |
| 2024-10-01 | -1.95 |
| 2024-09-30 | -2.04 |
| 2024-09-27 | -2.09 |
| 2024-09-26 | -2.04 |
| 2024-09-25 | -2.01 |
| 2024-09-24 | -2.01 |
| 2024-09-23 | -2.13 |
| 2024-09-20 | -2.28 |
| 2024-09-19 | -2.37 |